tbuckley/cabot-search huggingface dataset:
THU0189 Increased Expression of The Collagen Internalization Receptor Endo180 in Fibroblast-like Synoviocytes of Patients with Rheumatoid Arthritis
Authors: L. Yan, F.L. Kai, G.X. Hua
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hyperproliferative and invasiveness are the characteristics of fibroblast-like synoviocytes in rheumatoid arthritis (RA-FLSs), which contribute mainly to RA disease progression and ultimately to joint destruction. Endo180 is a recycling endocytic receptor that has functions to regulate cell migration and bind to internalize collagens. However, the expression of Endo180 in RA-FLSs and its underlying mechanisms remain unclear. <h3>Objectives</h3> The aim of this study was to examine the expression of Endo180 in RA-FLSs and the role it played in RA pathological process. <h3>Methods</h3> Tissues were collected from RA patients with joint replacement surgery or arthroscopy and RA-FLSs were obtained by tissue culture;Westren blotting was used to measure the expression of Endo180 in RA-FLSs. Chemically synthesized small interference RNA (siRNA) specifically targeting Endo180 gene was transfected into RA-FLSs by cationic liposome; The interference efficiency of Endo180-siRNA on the production of Endo180 RNA and protein was determined by RT-qPCR and Western blotting respectly; The proliferative inhibition rate was examined by CCK8 assay and the migration of RA-FLSs were examined by Transwell assay. <h3>Results</h3> Expression of Endo180 was obviously higher in fibroblast-like synoviocytes in RA than OA and the traumatic patients. And its expression level has positive correlation with disease activity described as DAS28. The proliferative inhibition rate was obviously higher in the Endo180-siRNA group than the control groups (P&lt;0.05) after transfection for 48h (16.31%±1.17%), 72h (23.53%±2.62%), 96h (18.01%±1.96%). Transwell migration assay demonstrated the RA-FLSs through the transwell membrane in Endo180-siRNA group (21.27±6.35) were lesser than the NC-siRNA group (80.20±11.12) (P&lt;0.05) and the blank control group (82.17±10.36) (P&lt;0.05). <h3>Conclusions</h3> Endo180 may play a role in the regulation of proliferation and migration of RA-FLSs, which may provide beneficial therapeutic effects in RA. <h3>References</h3> Melander MC, Jürgensen HJ, Madsen DH,et al. The collagen receptor uPARAP/Endo180 in tissue degradation and cancer (Review).Int J Oncol. 2015 Oct;47(4):1177–88. doi: 10.3892/ijo.2015.3120. Epub 2015 Aug 12. Madsen DH, Jurgensen HJ, Ingvarsen S, et al. Endocytic collagen degradation:a novel mechanism involved in protection against liver fibrosis. J Pathol. 2012 May;227(1):94–105. doi: 10.1002/path.3981. Epub 2012 Feb 17. <h3>Disclosure of Interest</h3> None declared
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Authors: P. Musto, K.C. Anderson, M. Attal, P.G. Richardson, A. Badros, J. Hou, R. Comenzo, J. Du, B.G.M. Durie, J. San Miguel, H. Einsele, W.M. Chen, L. Garderet, G. Pietrantuono, J. Hillengass, R.A. Kyle, P. Moreau, J.J. Lahuerta, O. Landgren, H. Ludwig, A. Larocca, A. Mahindra, M. Cavo, A. Mazumder, P.L. McCarthy, A. Nouel, S.V. Rajkumar, A. Reiman, E. Riva, O. Sezer, E. Terpos, I. Turesson, S. Usmani, B.M. Weiss, A. Palumbo
Journal: Annals of Oncology (2016)
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
Authors: D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, R Karjalainen, M M Majumder, P Ojamies, T Pemovska, K Wennerberg, C Heckman, K Porkka, M Wolf, T Aittokallio, O Kallioniemi
Journal: Leukemia (2016)

We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (AML) by generating eight resistant variants from MOLM-13 and SHI-1 AML cell lines by long-term drug treatment. These cells were compared with 66 ex vivo chemorefractory samples from cytarabine-treated AML patients. The models and patient cells were subjected to genomic and transcriptomic profiling and high-throughput testing with 250 emerging and clinical oncology compounds. Genomic profiling uncovered deletion of the deoxycytidine kinase (DCK) gene in both MOLM-13- and SHI-1-derived cytarabine-resistant variants and in an AML patient sample. Cytarabine-resistant SHI-1 variants and a subset of chemorefractory AML patient samples showed increased sensitivity to glucocorticoids that are often used in treatment of lymphoid leukemia but not AML. Paired samples taken from AML patients before treatment and at relapse also showed acquisition of glucocorticoid sensitivity. Enhanced glucocorticoid sensitivity was only seen in AML patient samples that were negative for the FLT3 mutation (P=0.0006). Our study shows that development of cytarabine resistance is associated with increased sensitivity to glucocorticoids in a subset of AML, suggesting a new therapeutic strategy that should be explored in a clinical trial of chemorefractory AML patients carrying wild-type FLT3.
Whole Exome Sequencing Analysis in AML with Normal Karyotype Not Harboring FLT3/ITD Mutation Reveals Novel Genetic Alterations.
Authors: Il-Kwon Lee, Namshin Kim, Yeo-Kyeoung Kim, Dennis Dong Hwan Kim, Quang Trinh, Mark D Minden, Chul Won Jung, Jun-Ho Jang, Hee-je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Jungwon Huh, Nan Young Kim, Li Yu, Yun Gyeong Lee, Sung-Hoon Chung, Jae-Sook Ahn, Deok-Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim
Journal: Blood (2012)
Longitudinal Evaluation of 110 Bone Marrow Aspirates of Multiple Myeloma Patients Treated with Lenalidomide Alone or in Combination with Autologous Stem Cell Transplantation or Alkylators for Early Dysplastic Signs
Authors: Sara A. Monaghan, Lijun Dai, Susanne M. Gollin, Markus Y. Mapara, Suzanne Lentzsch
Journal: Blood (2011)
18 F-FLT Positron Emission Tomography (PET)/CT Imaging in Myelofibrosis: A Non Invasive Method to Assess Bone Marrow Function and Extramedullary Hematopoiesis
Authors: Annalisa Andreoli, Laetitia Vercellino, Mathieu-John Ouvrier, Emmanuelle Barré, Bruno Cassinat, Virginie de Beco, Jean-Marc Zini, Pascal Merlet, Christine Dosquet, Christine Chomienne, Marie-Elisabeth Toubert, Jean-Jacques Kiladjian
Journal: Blood (2012)
Patient Navigation for Comprehensive Cancer Screenings in High-Risk Patients—Reply
Authors: Sanja Percac-Lima, Steven J. Atlas
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
P0830 : Early HCV kinetics during dual oral therapy with daclatasvir and asunaprevir
Authors: M. Nakamuta, M. Kohjima, K. Motomura, S. Tabata, T. Koyanagi, N. Yamashita, T. Sato, M. Yokota, N. Higuchi, T. Yoshimoto, T. Kurashige, M. Kawamoto, K. Fukuizumi, K. Kotoh
Journal: Journal of Hepatology (2015)
Health Care Reform in the United States
Authors: Caroline Meade, Connor Drake, Ralph Snyderman
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Analysis of Retroviral Vector Insertion Sites after T-Cell Directed Gene Therapy.
Authors: Akihiro Konno, G. Jayashree Jagadeesh, Daniele Moratto, Marita Bosticardo, Ingeborg Holt, Linda M. Muul, Shepherd H. Schurman, Tyra Wolfsberg, Fabio Candotti
Journal: Blood (2004)
Differential Expression of Genes Related to JAK-STAT Pathway Activation or Megakaryocyte Differentiation/Maturation in CD34+ Cells from Patients with Refractory Anemia with Ringed Sideroblasts and Thrombocytosis (RARS-T).
Authors: Luca Malcovati, Daniela Pietra, Matteo G. Della Porta, Andrea Pellagatti, Erica Travaglino, Emanuela Boveri, Anna Gallì, Elisa Rumi, Francesco Passamonti, Laura Cremonesi, Rosangela Invenizzi, Jaqueline Boultwood, Eva Hellström-Lindberg, James Wainscoat, Mario Cazzola
Journal: Blood (2007)
High Levels of Heat Shock Proteins 90 and 27 in CD34-Positive Cells from Myelodysplastic Syndromes (MDS) Are Associated with Higher Expression and Activation of Focal Adhesion Kinase (FAK) and with Disease Progression.
Authors: Françoise Solly, Pascale Flandrin-Gresta, Carmen Aanei, Jérôme Cornillon, Emmanuelle Tavernier, Denis Guyotat, Lydia Campos
Journal: Blood (2009)
PTH-040 Management of Common Bile Duct (CBD) Stones in Patients Unfit for Cholecystectomy, Does Elective Stent Change Programme Protect Against Further Biliary Complications After Clearance of CBD Stones in This Group?: Abstract PTH-040 Table 1
Authors: S Mahmood, J Krentz, C Kong, N Wang, H Kaltsidis, J Iqbal
Journal: Gut (2016)

<h3>Introduction</h3> Cholecystectomy is recommended in patients with biliary ductal stones after clearing the CBD with ERCP (endoscopic retrograde Cholangiopancreatography) due to increased risk of further recurrent biliary complication if gallbladder left in situ. There are no randomised controlled trials (RCTs) to date on the post ERCP management of biliary ductal stones in patients who are deemed unfit for cholecystectomy. Practice varies amongst ERCPists from routine ERCP with regular stent changes in this group to ERCP only when there is evidence of recurrent biliary complication due to recurrent ductal stones. <h3>Methods</h3> Retrospective review of ERCP database between Jan 2010 to Dec 2013 to review whether elective stent changes after CBD stone clearance offer any protection against biliary complications in patients deemed unfit for cholecystectomy. Inclusion criteria were, index ERCP for confirmed or suspected CBD stones, complete clearance of CBD at ERCP, gall bladder in situ and patient deemed unfit for cholecystectomy. Exclusion criteria were, gall bladder absent, patient fit for cholecystectomy but declined surgery, stricture seen at ERCP. Complications were defined as any subsequent unplanned ERCP from their index ERCP which achieved the inclusion criteria. <h3>Results</h3> A total of 1628 ERCPs in 1090 patients were reviewed. 356 patients fulfilled the inclusion criteria. 143 patients were in the regular stent change group (RSCG) and 213 patients in the non-stented group (NSG). The number of complications episodes leading to unplanned urgent or emergency ERCPs in RSCG were 40 (28%) whilst in NSG were 22 (10%). Median time between ERCPs was 7 months for the RSCG whilst it was 9 months for the NSG. A complete analysis of the data can be seen in the table below. <h3>Conclusion</h3> This study shows that patients who were on regular CBD stent change programme had more complications leading to unplanned ERCPs compared with patients who did not have a biliary stent placed. Therefore regular biliary stent changes in this group of patients with clear ducts offer no benefit in reducing complications. A randomised trial is needed to guide on the management of such patients <h3>Disclosure of Interest</h3> None Declared
Epimutation of the Tumor Suppressor Mechanism in 13q14.3 Involves Monoallelic Expression, Non-Coding RNA Genes and Deregulation of NFkB Signalling
Authors: Daniel Mertens, Angela Philippen, Nupur Bhattacharya, Cordula Tschuch, Melanie Ruppel, Peter Lichter, Hartmut Doehner, Stephan Stilgenbauer
Journal: Blood (2008)
High Body Surface Area (BSA) Is An Independent Risk Factor for Developing Bisphosphonate-Induced Osteonecrosis of the Jaw (ONJ)
Authors: Sikander Ailawadhi, Angie Elefante, Tracey L. O’Connor, Gregory E. Wilding, Wei Tan, Ellen Kossoff, Stephanie McCuthcheon, Kena C. Miller, Taimur Sher, Mehul Patel, Kelvin Lee, Asher A. Chanan-Khan
Journal: Blood (2008)
ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,
Authors: Katharina Wagner, Frederik Damm, Michael A Morgan, Felicitas Thol, Haiyang Yun, Gudrun Göhring, Brigitte Schlegelberger, Michael Heuser, Arnold Ganser, Jürgen Krauter
Journal: Blood (2011)
Abstract 19589: ACE Gene Dosage Impairs Cardiovascular Autonomic Dysfunction in Diabetic Animals
Authors: Oscar A Moraes, Kátia B Scapini, Karin Flues, Isabel C Lameirinhas, Cristiano T Mostarda, Maria C Irigoyen
Journal: Circulation (2016)

Clinical studies showed that the ACE I/D genotypes are not associated with the systolic or diastolic blood pressure. However, some studies have showed that high concentrations of ACE are deleterious to the kidney in a hyperglycemic environment. The aim of this study was assess hemodynamics and cardiovascular autonomic changes as well as the expression of renal angiotensin II in mice with 2 and 3 ACE gene copies, with or without diabetes streptozotocin , 50 mg/kg, IV; STZ). STZ induced diabetic were ACE2D (n= 10) and ACE3D (n=10). Systolic, diastolic, mean arterial pressure and heart rate were evaluated. Heart rate variability and renal angiotensin II were quantified. The data have shown a reduction in heart rate in diabetic animals compared to controls (ACE2=611 ± 14; ACE3: 596 ± 25; ACE2D: 347 ± 34; ACE3D: 317 ± 62bpm) and, as expected, blood glucose was higher in diabetic groups (ACE2=99 ± 7; ACE3: 97 ± 2; ACE2D: 467 ± 23; ACE3D: 513 ± 12 mg/dl). Although the variance of pulse interval was not different among the groups (ACE2D= 22,83 ± 4,51; ACE3D = 41,40 ± 13,31; ACE2= 38,50 ± 8,54; ACE3= 29,63 ± 4,76 ms2), ACE3D group showed increased sympathetic modulation (LF%: ACE3D= 60,78 ± 6,55; ACE2D= 33,25 ± 3,71; ACE2= 31,55 ± 4,07; ACE 3= 33,54 ± 7,0) and lower vagal modulation (HF%: ACE3D= 39,22 ± 6,55; ACE2D= 66,75 ± 3,71; ACE2= 68,45 ± 4,07; ACE3= 66,46 ± 7,00) than controls which resulted in an increased sympathovagal balance in the heart (LF/HF: ACE3D= 2,20 ± 0,68; ACE2D= 0,54 ± 0,10; ACE2= 0,48 ± 0,08; ACE 3= 0,57 ± 0,16) compared to the other groups. Moreover, Angiotensin II in the renal cortex was higher in ACE3D group compared to other groups (ACE3D= 1,70 ± 0,14; ACE2D= 0,97 ± 0,10; ACE2= 0,15 ± 0,03; ACE 3= 1,02 ± 0,22cel/mm2). A small increase in ACE levels induced by genetic manipulation in diabetic mice promoted autonomic injury. The development of cardiovascular autonomic changes in diabetes may be exacerbated by activation of the RAS.
Is Radiation Therapy Effective for DLBCL As a Salvage after Chemotherapy?: A Study of 180 Diffuse Large B Cell Lymphoma (DLBCL) Cases at a Single Institution
Authors: Aya Ouchi, Yokoyama Masahiro, Masahiko Oguchi, Kengo Takeuchi, Yoshiharu Kusano, Hideaki Nitta, Kyoko Ueda, Noriko Nishimura, Naoko Tsuyama, Yasuhito Terui, Noriko Usui, Keisuke Aiba, Kiyohiko Hatake
Journal: Blood (2014)
Genetically Modified EBV-Specific Cytotoxic T Lymphocytes Induce Regression Of EBV Lymphoproliferation Despite Immunosuppression In Xenografted Mice: A Novel Strategy For EBV-Associated Post-Transplant Lymphoproliferative Disease
Authors: Ida Ricciardelli, Jenny Brewin, Mike Blundell, Martin Pule, Persis Amrolia
Journal: Blood (2013)
PTH-042 A Feasibility, Pilot Study of Endoscopic Ultrasound Guided Solid Gold Marker Fiducial Placement in Oesophageal Cancer in Radiotherapy Planning
Authors: S Paterson, D McIntosh, D Grose, V MacLaren, AJ Stanley
Journal: Gut (2016)

<h3>Introduction</h3> There have been several different methods proposed for image guided radiotherapy in oesophageal cancer patients. One method described recently has been a fiducial solid gold marker sited under direct EUS guidance.<sup>1</sup> <h3>Methods</h3> This was a single centre, prospective, feasibility pilot study in a tertiary care cancer centre in Glasgow. Patients with oesophageal cancer, in whom radiotherapy was being planned between October 2015 and February 2016, underwent EUS to place solid gold fiducial markers of length 5 mm. 4 of these fiducials, in a new multi-fiducial delivery system (Cook®) with a 22 g delivery needle, were inserted through the channel of a linear EUS scope. The needle was inserted into the tumour and fiducials placed into the tumour under EUS guidance. 2 markers were placed at both the distal and proximal margin of the tumour where possible. The Five-point Likert scale<sup>2</sup> was used to determine technical outcomes from EUS placement at both EUS and planning CT. Median Likert scores are reported. Time to place the fiducial at time of EUS and any complications were recorded. <h3>Results</h3> A total of 25 fiducials have been placed in 7 patients. In 2 patients the tumour limited the passage of the EUS scope distally; therefore only proximal placement of the fiducials was undertaken. The median EUS accuracy of fiducial placement was within 5 mm from the outer rim of the target (Likert 2) and fiducials were deployed with minimal difficulty (Likert 2). The needle was clearly seen and easy to distinguish from surrounding tissue (Likert 1) and the fiducial markers were easy to see with minimal adjustments to the scope (Likert2). Mean time for fiducial deployment at EUS was 345 seconds. Mean time from EUS to planning CT scan was 28 days. At the planning CT fiducials were visualised in the tumour region in 6 of 7 patients. In these 6 patients they were visible in the tumour areas where placement was undertaken. The total number of fiducials identified was 15 out of 25 sited and they were easy to distinguish from surrounding tissue (Likert 2). There have been no complications reported. <h3>Conclusion</h3> EUS guided solid gold marker fiducial deployment is safe and feasible in patients with oesophageal cancer. There appears to be good correlation between fiducial position at EUS and subsequent radiotherapy planning CT. This may help to better target radiotherapy delivery. <h3>References</h3> 1 Endoscopy/EUS-guided fiducial marker placement in patients with esophageal cancer. <i>GastrointestEndosc</i>. 2015 Oct;<b>82</b>(4):641–9. doi:10.1016/j.gie.2015.03.1972. 2 Evaluation of a new endoscopic ultrasound-guided multi-fiducial delivery system: <i>Digestive Endoscopy</i>, <b>25</b>:615–621. doi:10.1111/den.12046 <h3>Disclosure of Interest</h3> None Declared
Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment
Authors: Daniel Delitto, Andrea E. Delitto, Bayli B. DiVita, Kien Pham, Song Han, Emily R. Hartlage, Brittney N. Newby, Michael H. Gerber, Kevin E. Behrns, Lyle L. Moldawer, Ryan M. Thomas, Thomas J. George, Todd M. Brusko, Clayton E. Mathews, Chen Liu, Jose G. Trevino, Steven J. Hughes, Shannon M. Wallet
Journal: Cancer Research (2016)

Abstract Cancer cells exert mastery over the local tumor-associated stroma (TAS) to configure protective immunity within the tumor microenvironment. The immunomodulatory character of pancreatic lysates of patients with cancer differs from those with pancreatitis. In this study, we evaluated the cross-talk between pancreatic cancer and its TAS in primary human cell culture models. Upon exposure of TAS to pancreatic cancer cell-conditioned media, we documented robust secretion of IL6 and IL8. This TAS response was MyD88-dependent and sufficient to directly suppress both CD4+ and CD8+ T-cell proliferation, inducing Th17 polarization at the expense of Th1. We found that patients possessed a similar shift in circulating effector memory Th17:Th1 ratios compared with healthy controls. The TAS response also directly suppressed CD8+ T-cell–mediated cytotoxicity. Overall, our results demonstrate how TAS contributes to the production of an immunosuppressive tumor microenvironment in pancreatic cancer. Cancer Res; 77(3); 672–83. ©2016 AACR.